Motexafin gadolinium
 |
|
|---|---|
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | ? |
| Identifiers | |
| CAS number | 156436-89-4 |
| ATC code | None |
| PubChem | CID 158385 |
| ChemSpider | 139341  |
| KEGG | D05080 |
| ChEBI | CHEBI:50161 |
| Chemical data | |
| Formula | C52H72GdN5O14 |
| Mol. mass | 1148.403 g/mol |
| SMILES | eMolecules & PubChem |
|
|
 (what is this?) (verify) |
|
Motexafin gadolinium (proposed tradename Xcytrin) is an inhibitor of thioredoxin reductase and ribonucleotide reductase. It has been proposed as a possible chemotherapeutic agent in the treatment of brain cancer.[1]
[edit] History
On May 9, 2006, a New Drug Application was submitted to the United States Food and Drug Administration (FDA) by Pharmacyclics, Inc.[2]
On December 2007, the FDA issued a not approvable letter for motexafin gadolinium.[3]
[edit] References
- ^ Richards G, Mehta M (2007). "Motexafin gadolinium in the treatment of brain metastases". Expert opinion on pharmacotherapy 8 (3): 351–9. doi:10.1517/14656566.8.3.351. PMID 17266469.
- ^ Pharmacyclics, Inc. press release - Pharmacyclics to Submit New Drug Application for Xcytrin for Treatment of Lung Cancer Patients With Brain Metastases
- ^ Pharmacyclics, Inc. press release - Pharmacyclics Receives Non-Approvable Letter from the FDA for Xcytrin for the Treatment of Lung Cancer Brain Metastases
 |
This biochemistry article is a stub. You can help Wikipedia by expanding it. |
